Epidemiology of influenza B in Australia: 2001-2014 influenza seasons

Influenza and other Respiratory Viruses

Volumn 11, Issue 2, 2017, Pages 102-109

  Moa, Aye M ^a   Muscatello, David J ^a   Turner, Robin M ^a   MacIntyre, Chandini R ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Australia; epidemiology; influenza B; Victoria lineage; Yamagata lineage

Indexed keywords

AGE; ARTICLE; AUSTRALIA; BASE MISPAIRING; CELL LINEAGE; CHILD; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; HUMAN; INFLUENZA A; INFLUENZA B; MAJOR CLINICAL STUDY; NONHUMAN; PRESCHOOL CHILD; SCHOOL CHILD; SEASONAL INFLUENZA; TIME; ADOLESCENT; ADULT; AGED; FEMALE; HEALTH SURVEY; IMMUNOLOGY; INFANT; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA, HUMAN; LABORATORY TECHNIQUE; MALE; MIDDLE AGED; PHYLOGENY; SEASON; VERY ELDERLY; VICTORIA; VIROLOGY; YOUNG ADULT;

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CLINICAL LABORATORY TECHNIQUES; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PHYLOGENY; POPULATION SURVEILLANCE; SEASONS; VICTORIA; YOUNG ADULT;

EID: 84991448045     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12432     Document Type: Article

References (65)

1. WHO. Influenza (Seasonal), World Health Organization. http://www.who.int/mediacentre/factsheets/fs211/en/. Accessed January 14, 2016.
2. Camilloni B, Neri M, Lepri E, et al. An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. Vaccine. 2010;28:7536–7541.
3. Grant KA, Carville K, Fielding JE, et al. High proportion of influenza B characterises the 2008 influenza season in Victoria. Commun Dis Intell Q Rep. 2009;33:328–336.
4. Yin-Coggrave M, Kadri Z. Type B influenza in Singapore. Singapore Med J. 1965;6:71–74.
5. Burnet FM, Stone JD, Anderson SG. An epidemic of influenza B in Australia. The Lancet. 1946;247:807–811.
6. Bedford T, Riley S, Barr IG, et al. Global circulation patterns of seasonal influenza viruses vary with antigenic drift. Nature. 2015;523:217–220.
7. Stuart-Harris CH, Schild GC, Oxford JS. Influenza: The Viruses and the Disease. London, England: Arnold; 1985.
8. McCann LJ, Suchanek O, McCarthy ND, Mannes T. Descriptive epidemiology of school outbreaks of seasonal influenza B during 2012/2013 in the Thames Valley United Kingdom. Public Health. 2014;128:1121–1124.
9. Fernandes EG, De Souza PB, De Oliveira MEB, et al. Influenza B outbreak on a cruise ship off the Sao Paulo coast, Brazil. J Travel Med. 2014;21:298–303.
10. Khan UH, Mir MA, Ahmad F, et al. An outbreak of influenza B in an isolated nomadic community in Jammu & Kashmir, India. Indian J Med Res. 2013;138:1012–1015.
11. Blyth CC, Foo H, van Hal SJ, et al. Influenza outbreaks during World Youth Day 2008 mass gathering. Emerg Infect Dis. 2010;16:809–815.
12. Muscatello DJ, Amin J, MacIntyre CR. et al. Inaccurate ascertainment of morbidity and mortality due to influenza in administrative databases: a Population-Based Record Linkage Study. PLoS One. 2014;9:e98446.
13. Paul Glezen W, Schmier JK, Kuehn CM, Ryan KJ, Oxford J. The burden of influenza B: a structured literature review. Am J Public Health. 2013;103:e43–e51.
14. Caini S, Huang QS, Ciblak MA, et al. Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study. Influenza Other Respir Viruses. 2015;9(Suppl 1):3–12.
15. Hannoun C. The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines. 2013;12:1085–1094.
16. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology. 1990;175:59–68.
17. Barr IG, Komadina N, Durrant C, Sjogren H, Hurt AC, Shaw RP. Circulation and antigenic drift in human influenza B viruses in SE Asia and Oceania since 2000. Commun Dis Intell Q Rep. 2006;30:350–357.
18. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012;8:81–88.
19. Chen R, Holmes E. The evolutionary dynamics of human influenza B virus. J Mol Evol. 2008;66:655–663.
20. WHO. Human infection with new influenza A (H1N1) virus: clinical observations from Mexico and other affected countries, May 2009. Wkly Epidemiol Rec. 2009;84:185–189.
21. Irving SA, Patel DC, Kieke BA, et al. Comparison of clinical features and outcomes of medically attended influenza A and influenza B in a defined population over four seasons: 2004–2005 through 2007–2008. Influenza Other Respir Viruses. 2012;6:37–43.
22. Daley A, Nallusamy R, Isaacs D. Comparison of influenza A and influenza B virus infection in hospitalized children. J Paediatr Child Health. 2000;36:332–335.
23. Carrat F, Vergu E, Ferguson NM, et al. Time lines of infection and disease in human influenza: a Review of Volunteer Challenge Studies. Am J Epidemiol. 2008;167:775–785.
24. Chi CY, Wang SM, Lin CC, et al. Clinical features of children infected with different strains of influenza B in southern Taiwan. Pediatr Infect Dis J. 2008;27:640–645.
25. Su S, Chaves SS, Perez A, et al. Comparing clinical characteristics between hospitalized adults with laboratory-confirmed influenza A and B virus infection. Clin Infect Dis. 2014;59:252–255.
26. Hite LK, Glezen WP, Demmler GJ, Munoz FM. Medically attended pediatric influenza during the resurgence of the Victoria lineage of influenza B virus. Int J Infect Dis. 2007;11:40–47.
27. Finelli L, Fiore A, Dhara R, et al. Influenza-associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics. 2008;122:805–811.
28. Lin CH, Huang YC, Chiu CH, Huang CG, Tsao KC, Lin TY. Neurologic manifestations in children with influenza B virus infection. Pediatr Infect Dis J. 2006;25:1081–1083.
29. Gutierrez-Pizarraya A, Perez-Romero P, Alvarez R, et al. Unexpected severity of cases of influenza B infection in patients that required hospitalization during the first postpandemic wave. J Infect. 2012;65:423–430.
30. Wie SH, So BH, Song JY, et al. A comparison of the clinical and epidemiological characteristics of adult patients with laboratory-confirmed influenza A or B during the 2011-2012 influenza season in Korea: a multi-center study. PLoS One. 2013;8:e62685.
31. Paddock CD, Liu L, Denison AM, et al. Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection. J Infect Dis. 2012;205:895–905.
32. WHO. Influenza. Vaccines. 2015; http://apps.who.int/gb/pip/pdf_files/Fluvaccvirusselection.pdf?ua=1. Accessed January 12, 2016.
33. Vijaykrishna D, Holmes EC, Joseph U, et al. The contrasting phylodynamics of human influenza B viruses. eLife. 2015;4:e05055.
34. Tricco AC, Chit A, Soobiah C, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013;11:153.
35. DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine. 2012;31:49–57.
36. Andrews N, McMenamin J, Durnall H, et al. Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results. Euro Surveill. 2014;19:5–13.
37. Kelly HA, Sullivan SG, Grant KA, Fielding JE. Moderate influenza vaccine effectiveness with variable effectiveness by match between circulating and vaccine strains in Australian adults aged 20-64 years, 2007-2011. Influenza Other Respir Viruses. 2013;7:729–737.
38. Kieninger D, Sheldon E, Lin WY, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged >18 years. BMC Infect Dis. 2013;13:343.
39. Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. 2013;31:770–776.
40. Domachowske JB, Pankow-Culot H, Bautista M, et al. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis. 2013;207:1878–1887.
41. DoH. The Department of Health, Australian Government. Influenza Laboratory Case Definition (LCD). http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-nndss-casedefs-cd_flu.htm. Accessed July 26, 2016.
42. DoH. The Department of Health, Australian Government. Influenza- Australian Influenza Surveillance Report and Activity Updates. http://www.health.gov.au/flureport. Accessed July 26, 2016.
43. DoH. The Department of Health, Australian Government. Influenza - National Influenza Surveillance Scheme annual reports. http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-pubs-annlrpt-fluannrep.htm. Accessed July 26, 2016.
44. AIHW. Australian Institute of Health and Welfare (AIHW) 2015. GRIM (General Record of Incidence of Mortality) books. 2013: All causes combined. Canberra: AIHW. 2015. http://www.aihw.gov.au/deaths/grim-books/. Accessed January 10, 2016.
45. Barr IG, Jelley LL. The coming era of quadrivalent human influenza vaccines. Drugs. 2012;72:2177–2185.
46. ABS. Australian Bureau of Statistics. Population by age and sex, Australia, States and Territories: 3101.0 - Australian Demographic Statistics, Jun 2014. http://www.abs.gov.au/ausstats/abs@.nsf/0/1CD2B1952AFC5E7ACA257298000F2E76?OpenDocument. Accessed April 14, 2016.
47. Heikkinen T, Ikonen N, Ziegler T. Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999–2012. Clin Infect Dis. 2014;59:1519–1524.
48. Chan PK, Chan MC, Cheung JL, et al. Influenza B lineage circulation and hospitalization rates in a subtropical city, Hong Kong, 2000-2010. Clin Infect Dis. 2013;56:677–684.
49. DoH. Australian Influenza Surveillance Report, No.10, 2012. Reporting period 29 September to 12 October, 2012. http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-ozflu-no10-12.htm. Accessed July 28, 2016.
50. ABS. Australian Bureau of Statistics. 3303.0.55.001 - Causes of Death, Australia: Doctor Certified Deaths, Summary Tables -2012. 2013; http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/3303.0.55.001Chapter32012. Accessed July 28, 2016
51. AIHW. Australian Institute of Health and Welfare. Principal diagnosis data cubes. http://www.aihw.gov.au/hospitals-data/principal-diagnosis-data-cubes/. Accessed July 28, 2016.
52. Caini S, Andrade W, Badur S, et al. Temporal patterns of influenza A and B in tropical and temperate Countries: what are the lessons for influenza vaccination? PLoS One. 2016;11:e0152310.
53. Mosnier A, Caini S, Daviaud I, et al. Ten influenza seasons in France: distribution and timing of influenza A and B circulation, 2003–2013. BMC Infect Dis. 2015;15:357.
54. Barr I, Vijaykrishna D, Sullivan S. Differential age susceptibility to influenza B/Victoria lineage viruses in the 2015 Australian influenza season. Euro Surveill. 2016;21. pii: 30118.
55. Socan M, Prosenc K, Ucakar V, Berginc N. A comparison of the demographic and clinical characteristics of laboratory-confirmed influenza B Yamagata and Victoria lineage infection. J Clin Virol. 2014;61:156–160.
56. Brottet E, Vandroux D, Gauzere BA, et al. Influenza season in Réunion dominated by influenza B virus circulation associated with numerous cases of severe disease, France, 2014. Euro Surveill. 2014;19.pii:20916.
57. Wong KK, Jain S, Blanton L, et al. Influenza-associated pediatric deaths in the United States, 2004–2012. Pediatrics. 2013;132:796–804.
58. Silva ML, Perrier L, Spath HM, et al. Economic burden of seasonal influenza B in France during winter 2010-2011. BMC Public Health. 2014;14:56.
59. You JH, Ming WK, Chan PK. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong. BMC Infect Dis. 2014;14:618.
60. Van Bellinghen LA, Meier G, Van Vlaenderen I. The potential cost-effectiveness of quadrivalent versus trivalent influenza vaccine in elderly people and clinical risk groups in the UK: a lifetime multi-cohort model. PLoS One. 2014;9:e98437.
61. Lee BY, Bartsch SM, Willig AM. The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine. 2012;30:7443–7446.
62. Chit A, Roiz J, Aballea S. An assessment of the expected cost-effectiveness of quadrivalent influenza vaccines in Ontario, Canada Using a Static Model. PLoS One. 2015;10:e0133606.
63. Reed C, Meltzer MI, Finelli L, Fiore A. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine. 2012;30:1993–1998.
64. Kelly HA, Grant KA, Tay EL, Franklin L, Hurt AC. The significance of increased influenza notifications during spring and summer of 2010–11 in Australia. Influenza Other Respir Viruses. 2013;7:1136–1141.
65. The Department of Health. Australia's notifiable disease status, 2009: annual report of the national notifiable diseases surveillance system. NNDSS Annual Report Writing Group. Commun Dis Intell. 2011;35:61–131.